CellGenix Technologie Transfer GmbH: 15 Years of Innovation and Leadership

05-May-2009 - Germany

2009 is a special year for CellGenix, according to the company. Cellgenix is celebrating its 15th anniversary. CellGenix was founded in May 1994 as a Spin-off from the University Medical Center Freiburg and has developed continuously ever since. 1997 the company launched the first GMP quality serum-free media for expansion of blood stem cells, followed in 2000 by serum-free medium in GMP quality for the differentiation of dendritic cells. The company is focused on the development, production and marketing of ex vivo, cell and protein therapeutics for cancer treatment as well as regenerative medicine, in particular for orthopedic patients.

According to the company, CellGenix is the market leader for development and manufacturing of GMP cytokines for clinical cell therapies. In 2007 the worldwide first IL-15 in GMP quality was released. CellGenix continues to strengthen its position as pioneer in this field: The United States Pharmacopeia (USP) is an independent regulatory authority for medicinal products manufactured or sold in the United States. IL-4 manufactured by CellGenix is the first cytokine to be accepted by the USP as reference standard for cell therapy applications. This documents CellGenix’ position as the manufacturer of products with highest quality and safety standards. At the beginning of this year, CellGenix has launched the eighth GMP cytokine.

CellGenix is now the only manufacturer of the cytokine bFGF in GMP quality and therefore able to meet the customers need in the growing market of stem cell research.

CellGenix’ product portfolio is complemented with the worldwide distribution of cell culture bags manufactured by the US Company American Fluoroseal. The culture and freezing bags are part of a sterile and closed Kit-System. They allow cultivation of T- and NK- cells and the maturation of different clinical relevant cells under GMP conditions.

Professor Felicia M. Rosenthal, CEO of CellGenix:” In these turbulent economic times, we can be proud to be holding and expanding our position in the biotechnology market. This was made possible thanks to our customers and committed employees, who helped us to make the last 15 years a success. Interesting developments in clinical cell therapy, for example current successes in stem cell research, are a great chance to built on CellGenix’ position as market leader. We are happy to embrace this challenge in the future.”

CellGenix employs almost 50 scientists and support staff members. The distribution network is developed worldwide. It has always been of great importance for the Freiburger Company to be in close contact with its customers which is being realized by its field representatives and customer service.

https://www.bionity.com/en/news/100448/cellgenix-technologie-transfer-gmbh-15-years-of-innovation-and-leadership.html